42 results on '"Mantzaris, Gerassimos J."'
Search Results
2. Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting
3. IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus
4. Molecular basis of vitamin D action in inflammatory bowel disease
5. Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases
6. Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study
7. Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months – Multicenter European cohort study
8. Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study
9. Efficacy and Safety Profile of Anti–tumor Necrosis Factor-α Versus Anti-integrin Agents for the Treatment of Crohn’s Disease: A Network Meta-analysis of Indirect Comparisons
10. Factors Associated With Short- and Long-Term Outcomes of Therapy for Crohn’s Disease
11. When can we cure Crohn's?
12. Dose optimization is effective in ulcerative colitis patients losing response to infliximab: A collaborative multicentre retrospective study
13. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: A prospective, two-year, single center, pilot study
14. Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: Biological roles and effects of TNF and TNF antagonists
15. The long-term efficacy of azathioprine does not wane after four years of continuous treatment in patients with steroid-dependent luminal Crohn’s disease
16. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease
17. 22 REAL-WORLD EFFECTIVENESS OF FIRST-LINE BIOLOGIC VEDOLIZUMAB IN CROHN'S DISEASE: ANALYSIS OF HIGHER TREATMENT EFFECT SUBPOPULATION FROM THE EVOLVE STUDY
18. Mo1634 COLD SNARE POLYPECTOMY VS HOT SNARE POLYPECTOMY VS ARGON PLASMA COAGULATION (APC) FOR 5-9 MM LEFT-SIDED COLORECTAL POLYPS: A PROSPECTIVE RANDOMIZED TRIAL
19. Mo1811 REAL-WORLD CLINICAL OUTCOMES OF BIOLOGIC-NAÏVE NONCOMPLICATED CROHN'S DISEASE PATIENTS TREATED WITH VEDOLIZUMAB: RESULTS FROM THE EVOLVE STUDY
20. Sa1748 CLINICAL EFFECTIVENESS AND SAFETY OF FIRST-LINE BIOLOGIC VEDOLIZUMAB AS A MONOTHERAPY OR COMBINATION THERAPY IN ULCERATIVE COLITIS AND CROHN'S DISEASE PATIENTS: RESULTS FROM THE EVOLVE STUDY
21. Sa1741 A REAL-WORLD COMPARISON OF THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND ANTI-TNF THERAPIES IN EARLY TREATMENT INITIATION WITH FIRST-LINE BIOLOGIC THERAPY IN ULCERATIVE COLITIS: RESULTS FROM EVOLVE
22. Mo1905 – A Retrospective Study to Examine the Impact of Crohn’s Disease Duration on Adalimumab’s Effectiveness to Achieve Remission in Patients Bearing Poor Prognostic Factors: the ‘Modify’ Study
23. Su1858 – Real-World Effectiveness and Safety of Vedolizumab and Anti-TNF in Biologic-Naive Ulcerative Colitis Patients: Results from the Evolve Study
24. Su1859 – Real-World Effectiveness and Safety of Vedolizumab and Anti-TNF in Biologic-Naive Crohn’s Disease Patients: Results from the Evolve Study
25. Su1254 FACTORS PREDICTING INCOMPLETE SMALL BOWEL CAPSULE ENDOSCOPY
26. Tu1615 - Serum Proteomic Analysis of Patients with Irritable Bowel Syndrome
27. Sa1895 - Predictors of Tissue Healing in Ulcerative Colitis Patients Treated with Anti-TNF
28. Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel
29. Su1809 Combining Anti-Inflammatory Treatment With Antiviral Treatment in Severe CMV Positive Ulcerative Colitis Does Not Affect Colectomy Rate: A Retrospective Multicenter Study
30. 19 Infliximab Discontinuation Is Associated With a Higher Risk for Relapse in Patients With Ulcerative Colitis in Remission: A Multinational Collaborative Retrospective Study
31. Faecal calprotectin but not C-Reactive Protein (CRP) or Crohn's Disease Activity Index (CDAI) may predict post-operative endoscopic recurrence of Crohn’s Disease
32. Reply to Dr. Yamamoto's letter
33. Long term safety and efficacy of H1N1 vaccine in a single-center cohort of IBD patients treated with immunomodulators and/or anti-TNFα biologics
34. Evolution of Endoscopic Activity Scores in Patients With Crohn's Disease Under Azathioprine and/or Infliximab: A Post-Hoc Analysis of the Sonic Data
35. Pilot Study of Adalimumab for Early Prevention and/or Treatment of Post-Operative Endoscopic Recurrence of Crohn's Disease
36. Serum Proteome Profile of Crohn's Disease Patients Treated With Infliximab: A Pilot Study
37. Short and Long Term Outcome of Infliximab Scheduled Therapy for Acute, Severe Ulcerative Colitis. A Prospective, Open Label, Single-Centre, Two-Year Study
38. Association of Steroid-Free Clinical Remission and Complete Mucosal Healing at 6 Months With Clinical Outcome at 1 Year: A Post-Hoc Analysis of SONIC trial Data
39. S2044 Effect of a Gluten Free Diet on Bone Mineral Density in Patients With Celiac Disease
40. M1069 A Lyophilized Form of S. Boulardii Enhances the Effect of Omeprazole-Triple Therapy in Patients with Organic or Functional Dyspepsia
41. 751f One Year Data from the Sonic Study: A Randomized, Double-Blind Trial Comparing Infliximab and Infliximab Plus Azathioprine to Azathioprine in Patients with Crohn's Disease Naive to Immunomodulators and Biologic Therapy
42. A comparison of the effect of budesonide and mesalamine on the quality of life in patients with steroid-dependent Crohn's disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.